Biotech and Pharmaceuticals Pharmaceuticals

  • Doctor holding test tube

    In today's world, the process of providing access to affordable healthcare should be easier than it is. Globally, we're all affected by the rising costs of healthcare in the face of an aging population – increasing expenditures for healthcare is a challenge in every country where Teva has a presence.

  • doctor

    Every year millions of the world’s poorest people die from curable or preventable infectious diseases or suffer unnecessary ill health because they do not have access to basic health care services, including essential medicines and vaccines. The reasons for this are complex and plentiful....but these problems cannot be an excuse for inaction, writes Andrew Witty, CEO of GlaxoSmithKline.

  • Marijuana & Money: A CNBC Special Report

    UK-based bio-technology firm GW Pharmaceuticals launched the first prescription medicine derived from cannabis Monday, following regulatory approval late last week.

  • blood_press_125x100.jpg

    Just because you're busy running a company, doesn't mean you have to run yourself into the ground.  Get proactive—and we don't mean travel more.  See a doctor to learn  whether high blood pressure, cancer, diabetes and other serious diseases may be waiting down the road.

  • bashful_woman_200.jpg

    A German drug giant says it has stumbled upon such a pill and is trying to persuade the Food and Drug Administration that its drug can help restore a depressed female sex drive.  The NYT reports.

  • FDA

    Federal health regulators said Wednesday the first pill designed to boost the female sex drive failed to make a significant impact on libido in two studies.

  • Doctor holding test tube

    Thousands of researchers presented studies at the recent cancer forum, but none more significant than those for patients with advanced melanoma.

  • Donald Drapkin, Chairman of Casablanca Capital, explains the battle between CVS and Walgreen's and why pharmacy benefit plans 'just don't work.'

  • doc_patient_shot_200.jpg

    There is no “quick fix” for cancer, no clear spot of light at the end of the tunnel. This cautious realization is that the fight against cancer is going to take more time than we thought.

  • drug_prices_sm.jpg

    Sales of a vaccine for late-stage prostate cancer, Dendreon’s Provenge, are expected to reach $1 billion in the first two years, analysts have predicted. This drug, one of several being showcased at the American Society of Clinical Oncologists meeting, represent a trend in which drugs treat a subgroup of cancer sufferers within the larger disease.

  • Doctor holding test tube

    They are the highly trained, generally well-paid employees in the vanguard of American innovation: people who work in biotechnology labs. But the cutting edge can be a risky place to work.

  • Drug developer Celgene is expected to release data on from two studies in coming weeks, and the bulls are looking for a rally.

  • This company not only should escape Europe’s troubles, it should benefit from them.

  • This trend is driving the markets right now.

  • I hate goodbyes. So, rather than get all sappy and sentimental, I'm just gonna say, "Thank you."

  • merck_entrance_200.jpg

    The Supreme Court said Tuesday that investors who lost millions when Merck pulled its blockbuster pain drug Vioxx off the market can go ahead with a lawsuit against the pharmaceutical giant.

  • Amgen says better sales of its anti-infection drugs helped lift first-quarter profit 15 percent, but cautions that health care reform measures will tamp down full-year results.

  • My last day at CNBC is May 7th. I've decided to make a career change. Because my next act will include working within the health care sector, to avoid even the appearance of a conflict in my remaining days here at CNBC, I won't be blogging or reporting anymore about stock-related stories on my previous beat.

  • Amsterdam coffee shop

    Portugal and Spain  provide as good as an example as The Netherlands. In both countries, the drug is illegal, but you'd never know it based on some quirky technicalities.  The general trend is about prevention, not punishment.

  • Status: Settled 2005Amount: $2.5 billionInvestors in AOL Time Warner stock sued the company for fraud under federal securities law.  The company was alleged to have improperly accounted for dozens of advertising transactions between 1998 and 2002. The alleged transactions created the appearance that they were generating revenue when, in reality, were just shifting money back and forth. The alleged false earnings statements inflated the company’s value by $1.7 billion.

    Here, we present the top 10 class-action lawsuits in the United States either won, settled or pending, and in terms of damages sought as compiled by LawInfo.com.